This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Edmond Schuller, MD
Laboratoire de Neuro-Immunologie Hôpital de la Salpétrière 75651 Paris Cedex 13 France

Arch Neurol. 1994;51(3):234.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

We read with great interest the article by Achiron and colleagues, entitled "Open Controlled Therapeutic Trial of Intravenous Immune Globulin in Relapsing-Remitting Multiple Sclerosis."¹ Unfortunately, the open trial published 10 years ago by our group² was not cited by the authors. Our experience concerned 31 patients with multiple sclerosis, with a mean duration of treatment of about 4 years. After treatment, health conditions improved significantly (P<.01) in 11 patients, no change was observed in nine patients, and deterioration continued in 11 patients. The disease progression (ratio of disability to duration of the disease in years) declined significantly in 20 patients, and the deterioration in group 3 was not significant, suggesting that this therapy has had no deleterious effect in the patients.

This attempt was continued and is still used. A screening for antibodies to human immunodeficiency virus type 1 was decided in 1985,³ concerning 42 patients . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?